Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections

YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing that the Company’s lead product candidate, exebacase, which has been designated as a Breakthrough Therapy for development as a treatment for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections by the FDA, was effective in a rabbit model of implant-associated osteomyelitis. Additional data was also presented which further supports that exebacase has a low propensity for the development of antimicrobial resistance, and also has the ability to suppress antibiotic resistance to standard of care antibiotics in vitro. These data were recently presented at the ASM Microbe Conference held in Washington, D.C. from June 9-13, 2022.